University of Groningen

Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche

Castrechini, N. M.; Murthi, P.; Gude, N. M.; Erwich, J. J. H. M.; Gronthos, S.; Zannettino, A.; Brennecke, S. R.; Kalionis, B.; Brennecke, S.P.

Published in:
Placenta

DOI:
[10.1016/j.placenta.2009.12.006](https://doi.org/10.1016/j.placenta.2009.12.006)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2010

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Castrechini, N. M., Murthi, P., Gude, N. M., Erwich, J. J. H. M., Gronthos, S., Zannettino, A., Brennecke, S. R., Kalionis, B., & Brennecke, S. P. (2010). Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche. *Placenta*, 31(3), 203-212. <https://doi.org/10.1016/j.placenta.2009.12.006>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Mesenchymal stem cells in human placental chorionic villi reside in a vascular Niche

N.M. Castrechini^{a,b}, P. Murthi^{a,b}, N.M. Gude^{a,b}, J.J.H.M. Erwich^c, S. Gronthos^d, A. Zannettino^d, S.P. Brennecke^{a,b}, B. Kalionis^{a,b,*}

^a Pregnancy Research Centre, Department of Perinatal Medicine, The Royal Women's Hospital Locked Bag 300, Cnr. Grattan St. and Flemington Rd., Parkville, Victoria 3052, Australia

^b Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Victoria 3052, Australia

^c Department of Obstetrics and Gynaecology, University Medical Centre Groningen, PO BOX 30001, 9700 RB Groningen, The Netherlands

^d Division of Haematology, Institute of Medical and Veterinary Science/ Hanson Institute, Adelaide 5000, SA, Australia

ARTICLE INFO

Article history:

Accepted 8 December 2009

Keywords:

Stem cells
Chorionic villi
Mesenchymal
Vascular niche

ABSTRACT

The chorionic villi of human term placentae are a rich source of mesenchymal stem cells (PMSCs). The stem cell “niche” within the chorionic villi regulates how PMSCs participate in placental tissue generation, maintenance and repair, but the anatomic location of the niche has not been defined. A number of cell surface markers for phenotypic characterisation of mesenchymal stem cells (MSCs) were employed to identify the stem cell niche within the chorionic villi of first trimester and term human placenta. This included antibodies to pericyte cell surface markers STRO-1 and 3G5, which have been used to identify mesenchymal stem cells in other tissues, but have not been studied in placental tissues. PMSCs were isolated from term human placentae and shown to have stem cell properties by their ability to grow on untreated plastic culture ware, capacity for forming clones (i.e. clonogenicity) and their capability to differentiate into adipocytes, chondrocytes and osteocytes. Western analysis confirmed that STRO-1 and 3G5 are present in placental protein extracts and in PMSCs. Immunocytochemistry revealed PMSCs were positive for MSC cell surface markers (STRO-1, 3G5, CD105, CD106, CD146, CD49a, α -SMA) and negative for haematopoietic stem cell markers (CD117, CD34) and endothelial markers (CD34, vWF). Immunohistochemistry with antibodies to MSC cell surface markers on first trimester and term tissues revealed a vascular niche for PMSCs. Dual-label immunofluorescence analysis was used to compare STRO-1 antibody staining with that of endothelial cell marker vWF and found no significant overlap in staining. This indicated that some PMSCs have a pericyte-like phenotype. We propose that the vascular niche harbours a pool of PMSCs that can give rise to committed progenitors for tissue maintenance and repair, and that PMSCs contribute to vessel maturation and stabilization.

© 2009 Elsevier Ltd. All rights reserved.

1. Introduction

The chorionic villi from human term placentae are a rich source of MSCs. The potential utility of PMSCs in therapeutic and regenerative medicine drives current research into their *in vitro* properties. The (trans)differentiation potential of PMSCs *in vitro* is now well known but there is scant knowledge of the natural distribution and biology of PMSCs in the chorionic villi of the placenta.

PMSCs are readily isolated from term placentae using a variety of methods. The most popular, routinely used method involves

mechanical mincing of the chorionic placental tissue, followed by enzymatic digestion and seeding in stem cell-specific medium [1]. PMSCs selectively attach to the plastic cultureware, proliferate rapidly and are usually prepared without additional enrichment strategies [2]. PMSCs can be differentiated *in vitro* under specific stimulatory environments into derivatives of the mesenchymal cell lineage such as osteocytes, adipocytes, myocytes and chondrocytes [1,3–7]. In addition, there is evidence of differentiation *in vitro* into cell types characteristic of other lineages such as hepatocyte-like cells and neural-like cells [3,4,7–11], but *in vivo* evidence for such differentiation is very limited.

Various combinations of cell surface markers are used for the phenotypic characterisation of PMSC *in vitro*. Common positive markers for PMSCs are also used to identify MSCs from other sources and include CD90 (Thy-1), CD105 (endoglin), CD29 (beta 1 integrin), CD44 (hyaluronic acid), and CD73 (lymphocyte-vascular adhesion

* Corresponding author. Department of Perinatal Medicine, The Royal Women's Hospital Locked Bag 300, Cnr. Grattan St. and Flemington Rd., Parkville, Victoria 3052, Australia. Tel.: +61 3 83453748; fax: +61 3 83453746.

E-mail address: bill.kalionis@thewomens.org.au (B. Kalionis).

protein 2). PMSCs are consistently negative for specific endothelial cell surface markers [e.g. von Willebrand Factor (vWF), CD34 and CD45] and haematopoietic stem cell markers (CD34, CD117).

Despite the extensive phenotypic characterisation of PMSCs *in vitro* with cell surface markers, there have been no studies to exploit multiple cell surface markers to identify the microenvironment, or niche, of PMSCs in the chorionic villi of placental tissues.

The stem cell niche is a highly balanced microenvironment that allows stem cells to survive and remain quiescent and then respond by replicating, migrating and differentiating to replace or repair tissue when needed [12–14]. This balance between stem cell proliferation and differentiation is regulated through intracellular integration of a multitude of signals initiated by internal and external stimuli. The identification of the anatomic location of the stem cell niche within the placental chorionic villi not only provides clues as to the nature of these stimuli but can also reveal additional roles for stem cells in placental development and function.

Recent studies have employed a panel of cell surface markers associated with endothelial cells (vWF, CD34), pericytes and endothelial cells (CD146), smooth muscle cells (α -smooth muscle actin), and pericyte-specific antigens (STRO-1 and 3G5) to detect cells with MSC properties in bone marrow, periodontal ligament, dental pulp and human adipose tissue [15–18]. Importantly, these antibody markers were used to define the MSC niche in these tissues. Furthermore, in these studies the STRO-1, 3G5 and CD146 antibodies were able to enrich for subpopulations of progenitor MSCs [15,18–22] that have a high capacity to form fibroblastoid colonies *in vitro* (called the CFU-F population) [22], which is an important property of stem cells. CFU-F colonies derive from a single stem cell and have the ability to differentiate into many of the cell types that are characteristically derived from the niche [23].

Although STRO-1 and 3G5 antibodies have been used to identify *in vitro* cultured MSCs derived from the various sources described above, they have not been used for the characterisation of the PMSC niche in the chorionic villi. FACS analysis showed that freshly isolated cells from the placental chorionic villi express STRO-1 and that expression fell to undetectable levels after passage 3 of *in vitro* culture [3]. Another study however, could not detect STRO-1 expression in PMSCs [2]. 3G5 has not been tested as a cell surface marker for PMSCs and the expression patterns of STRO-1 and 3G5 in the placenta are not known.

Another marker which has been used to enrich the CFU-F population is CD49a [24]. Integrin α 1 (CD49a/VLA-1), which is the receptor for laminin and collagen, was also investigated. The CD49a cell surface marker has also been used to identify both human bone marrow mesenchymal stem cells [25] and PMSCs [1].

FACS analysis has been used routinely for the analysis of PMSC populations [1,3–7]. In this study, we used cell surface markers, including STRO-1, 3G5, CD146 and CD49a that enrich CFU-F populations, to characterise PMSC preparations by immunohistochemistry. PMSC properties were further demonstrated by CFU-F and differentiation assays. Finally, we used immunohistochemical and immunofluorescence studies to identify the anatomic location of the stem cell niche and to determine differences in the stem cell niche between early and late pregnancy.

2. Materials and methods

2.1. Patient details

There were 20 term human placentae collected for this study, with an average patient gestation of 38.5 ± 1.6 weeks (mean $\pm$ SD), maternal age of 32.9 ± 6.9 years, baby weight of 3419.0 ± 438.9 g

and placental weight of 641.6 ± 90.4 g. Delivery mode was either elective Caesarean section (15/20) or vaginal delivery (5/20) and there were 12/20 males and 8/20 females. All samples were obtained from uncomplicated pregnancies and were therefore considered normal.

First trimester placental tissues were collected with the consent and the approval of the Federation of Medical Scientific Associations of the Netherlands. The Research and Ethics Committee of the Royal Women's Hospital (Victoria, Australia) approved the use of term placenta tissue for this work. The study was performed in accordance with the National Health and Medical Research Council of Australia guidelines. All placental tissues were collected from healthy women who had medically uncomplicated pregnancies. Five first trimester samples were used in this study.

2.2. Antibodies

Monoclonal antibodies STRO-1 (mouse IgM anti-human stromal stem cells) [22] and 3G5 (IgM anti-human islet cells; ATCC) were used as undiluted tissue culture supernatants with total protein concentration of 4.7 mg/ml and 3.5 mg/ml, respectively. CD146 (used at 4 μ g/ml), was a gift of S. Gronthos and A. Zannettino, Institute of Medical and Veterinary Science, Adelaide, Australia]. Other antibodies included rabbit anti-integrin CD49a/VLA-1 (used at 8 μ g/ml), mouse anti-human CD105 and CD106 (used at 1 μ g/ml and 5 μ g/ml respectively) (all from Millipore/Chemicon, Massachusetts, USA) and mouse anti-human α -smooth muscle actin (α -SMA, used at 4 μ g/ml) (Sigma-Aldrich, St. Louis, USA). Endothelial cell surface markers were rabbit polyclonal anti-human vWF and mouse anti-human CD34 (QEnd/10) (Labvision/Neomarkers, California, USA) (both used at 1 μ g/ml), which have been previously used for immunohistochemical studies of the placenta [26]. The haematopoietic stem/progenitor cell surface marker used was mouse anti-human CD117 (used at 5 μ g/ml) (Millipore/Chemicon, Massachusetts, USA). Control monoclonal antibody FDO66Q (Q66) (mouse IgG1 anti-human trophoblast cells) [27] was used at 1 μ g/ml and obtained from Flinders Technologies, Pty. Ltd. Adelaide, Australia. Non-immune rabbit serum (NIRS, used at 5 μ g/ml), control mouse monoclonal antibody 1A6.12 (IgM), which was used as an undiluted tissue culture supernatant with a total protein concentration of 10 mg/ml (gift of S. Gronthos and A. Zannettino, Institute of Medical and Veterinary Science, Adelaide, Australia) was used as a negative control. The other negative control was X63 (mouse IgG1 anti-human), from the cell line P3X63.Ag8, which has no known cross-reactivity with human tissue, was used at 5 μ g/ml [28] and was obtained from the Department of Immunology (Flinders Medical Centre, Adelaide, Australia).

2.3. First trimester placental sample collection

First trimester samples (10–12 weeks gestation) were collected by chorionic villus sampling by a transcervical approach, using a biopsy catheter (Cook, K-CMA-5000), at the University Hospital Groningen, The Netherlands. The samples collected were required for cytogenetic diagnosis and the surplus tissue was paraffin embedded and donated to this study.

2.4. Term placental sample collection

Term placentae were from either from normal vaginal deliveries or elective Caesarean sections and samples were processed within 20 min of delivery.

Following collection, the decidual surface of the placenta was removed and 2.5 cm cubes of placental tissue were taken from a central cotyledon of the villous vascular bed. The samples were

Fig. 1. Western analysis was used to show that CD49a, 3G5 and STRO-1 were expressed in both PMSC protein extracts (PMSC) and in term placental tissue homogenates (tissue). (A) The CD49a antibody detected bands at 210 kDa, 80 kDa and 70 kDa band in tissue and PMSC protein extracts. (B) The 3G5 antibody, detected a predominant immunoreactive band at 15 kDa, with minor bands at 10 kDa and 30 kDa for both term placental tissue homogenate and PMSC protein extracts. (C) The STRO-1 antibody detected a prominent 27 kDa band for both term placental tissue homogenate and PMSC protein extracts. Minor bands at 18 kDa and 50 kDa were also observed. The control blots with NIRS (A) for CD49a/VLA-1 (A) and IA6.12 (B, C) for STRO-1 and 3G5 showed no bands.

rinsed in 0.9% saline and either snap frozen in liquid nitrogen for protein extraction, formalin fixed for paraffin embedding, encased in Cryomatrix (Zeiss, Australia) and snap frozen for immunohistochemistry, or placed in warmed Hanks Balanced Salt Solution (Invitrogen/Gibco, California, USA) for stem cell isolation.

2.5. Isolation of stem cells from term placental tissue

Placental mesenchymal stem cells isolated from term placenta were prepared as previously described by [1] with the modifications described below. Placental sections of about 10 g (2.5 cm cubes) were extensively minced and then centrifuged at 550 g for 5 min. The pellet was then haemolysed in red blood cell lysis buffer (155 mM NH_4Cl , 10 mM KHCO_3 , 0.1 mM EDTA, pH 8.0), centrifuged at 550 g for 5 min at room temperature. The pellet was incubated at 37 °C in 0.05% Trypsin-EDTA solution (Invitrogen/Gibco, California, USA) for 10 minutes, resuspended twice in 50% α -MEM medium/50% FBS, subjected to centrifugation at 550 g for 10 min at room temperature and then plated in α -MEM medium supplemented with 20% FCS, 0.02% L-ascorbate-2-phosphate, 1% L-Glutamine, 0.5% penicillin/streptomycin, 0.5% Fungizone and 1% Tylosin. Cells were maintained in culture at 37 °C and 5% CO_2 . Cell viability and number was determined by Trypan Blue exclusion assay (Invitrogen, California, USA).

2.6. Western immunoblotting

Total protein from cultured stem cells was prepared using extraction buffer containing 50 mM glycine, 1 mM AEBSEF and 0.5% Triton X-100. Cells were lysed by three freeze–thaw cycles and then gently homogenised using a 19-gauge needle before centrifugation at 3000 g for 5 min. Total protein was extracted from whole placental tissues as described previously [26]. Briefly, 500 mg of snap-frozen placental tissue was added to 4 ml of extraction buffer [50 mM glycine, 1 mM AEBSEF, 5 mM EDTA (pH 8) and 0.5% Triton X-100]. Samples were then homogenised on ice, using an Ultra Turrax T25 mechanical homogeniser for 1 min, followed by centrifugation at 2500 g for 10 min. Total protein concentration in the supernatants was determined by Pierce (Thermo Fisher/Pierce, MA, USA) protein assay reagent using bovine serum albumin (Sigma, Australia) as the standard.

Immunoblotting was performed according to methods described previously under reducing conditions [26]. Briefly, 25 μg of protein per lane was diluted in SDS-PAGE loading buffer (100 mM Tris–HCl, pH 6.8, 200 mM β -mercaptoethanol, 4% SDS, 0.2% bromophenol blue, 20% glycerol) and boiled for 5 min per lane

was fractionated using 10%Tris–HCl polyacrylamide (BioRad, California, USA) gel electrophoresis and then transferred to nitrocellulose membranes. Membranes were incubated in blocking agent consisting of 5% skim milk powder in Tris-buffered saline (pH 7.4) for 1 h at room temperature, followed by incubation with primary antibodies to either STRO-1, 3G5 or CD49a overnight at 4 °C. Membranes were then incubated with goat anti-mouse or donkey anti-rabbit biotinylated secondary antibody (Dako, Glostrup, Denmark), followed by streptavidin–HRP (Dako, Glostrup, Denmark). Tyramide Signal Amplification (Perkin–Elmer, MA, USA) was used, following the manufacturer's instructions, to amplify the immunoreactivity. Immunoreactivity was visualised by chemiluminescence using the ECL-Plus kit (G.E. Healthcare, Buckinghamshire, England) and autoradiography.

2.7. Immunocytochemistry

Cells for immunocytochemical analysis were seeded into an 8-well chamber slides (BD, Australia) at a density of 50–100 cells/well, were maintained at 37 °C in 5% CO_2 for at least 48 h and then fixed in 10% formalin for 20 min. Antibody staining and detection was as described below.

2.8. Immunohistochemistry

Immunohistochemical analysis was carried out as described previously [26]. Briefly, five micron thick sections of paraffin, or Cryomatrix-embedded whole placental tissue samples, were cut for immunohistochemistry and placed onto coated slides

Table 1
Summary of cell surface marker staining on cultured PMSCs.

Antibody	Staining intensity ^a
X63	–
NIRS	–
FDO66Q	–
3G5	+/-
CD34	–
CD146	++
STRO-1	+
CD49a/VLA-1	++
vWF	–
CD105	+
CD117	–
CD106	+
α -SMA	++

^a ++, strong staining; +, moderate staining; +/-, weak staining; –, no staining.

Fig. 2. Immunocytochemical staining of isolated PMSCs. Cells were negative for X63 (a), vWF (b) and NIRS, FDO66Q, CD34, and CD117 (data not shown). Cells were positive for 3G5 (c), CD146 (d), CD49a/VLA-1 (e), α -smooth muscle actin (α -SMA) (f), STRO-1 (g) and CD106 (h) (magnification 200 $\times$). Cultured cells were clonogenic as shown by colony forming unit assay (Fig. 1i) (magnification 100 $\times$).

(Superfrost Plus slides, Menzel-Glaser, Braunschweig, Germany). Paraffin embedded samples were de-waxed in Xylene and rehydrated in graded ethanol before use.

Immunostaining was performed using primary antibodies and a Histostain-Plus™ Broad Spectrum Kit (Invitrogen/Zymed, California, USA). A Tyramide Signal Amplification (TSA) kit (Perkin-Elmer, MA, USA) was used to amplify immunoreactivity from antibodies to 3G5 and STRO-1 according to the manufacturer's instructions. Detection was either by 3-amino-9-ethyl-carazole (AEC) (Zymed, California, USA) staining with 0.05% methyl green counterstain or by 3,3-diaminobenzidine (DAB) staining with haematoxylin counterstain, depending on antibody compatibility. All slides were mounted in 80% glycerol, visualised using a Zeiss Axioscop microscope, and analysed with Axiovision software (Carl Zeiss Inc. New York, USA).

2.9. Dual-labelling immunofluorescence

Frozen placental sections were used for staining and were treated in the same manner as for immunohistochemistry described above with the following modifications. Polyclonal rabbit anti-human vWF antibody was incubated with mouse anti-human STRO-1. Donkey anti-rabbit Cy-3 conjugated secondary antibody and goat anti-mouse FITC-conjugated secondary antibody (Millipore/Chemicon, Massachusetts, USA) followed. A mountant containing DAPI nuclear counterstain (CAMBIO, Cambridge, UK) was

used. Sections were visualised using a fluorescence microscope (Carl Zeiss, Inc., New York, USA). The staining for vWF (Cy3), STRO-1 (FITC), as well as DAPI nuclear staining, was detected with individual filters and was subsequently composited using the Adobe Photoshop Elements version 4.

2.10. Colony Forming Unit (CFU) assay

Colony forming efficiency was assessed using methods described previously [29]. Isolated PMSCs at passage two were seeded into six well plates at a density of 100 cells/well in α -MEM medium supplemented with 20% FCS, 0.02% L-ascorbate-2-phosphate, 1% L-Glutamine, 0.5% penicillin/streptomycin, 0.5% Fungizone and 1% Tylosin. Unreplenished day 14 cultures were fixed with 10% formalin and then stained with haematoxylin. Aggregates of ≥ 50 cells were scored as colonies.

2.11. Differentiation of PMSCs

PMSCs were seeded into 8-well chamber slides at a density of 100 cells per well. Cells incubated with α -MEM medium (supplemented with 10% FCS, 0.02% L-ascorbate-2-phosphate, 1% L-Glutamine, 0.5% penicillin/streptomycin, 0.5% Fungizone and 1% Tylosin) were used as the control. PMSCs were incubated with adipogenic or chondrogenic or osteogenic differentiation medium. The medium in each well was replenished every 48 h. Differentiation media were

Fig. 3. Differentiation assays for cells in the mesenchymal lineage. Control undifferentiated PMSCs (a, c, e) were grown in α -MEM medium alone. Panels (b), (d), (f) show cells grown for the same time as the controls but in α -MEM medium containing differentiation factors. Staining was with Alcian Blue for chondrocytes (a, b), Oil red O for adipocytes (c, d) and Alizarin Red for osteocytes. Magnification for panels (a) and (b) was 100 $\times$ and for panels (c)–(f) was 200 $\times$. The arrows in panel (d) show lipid droplets. Scale bars represent 50 μ m.

purchased as bullet kits (Cambrex, New Jersey, USA) and differentiation was induced as per manufacturer's instructions. At the end of experimental procedures, the cells were fixed in 10% formalin and stained. Cell stains for mesenchymal stem cells were carried out as described previously [10,30,31]. Cells were stained with Oil Red-O and haematoxylin counterstain to detect adipocytes and Alizarin red solution to detect osteocytes as recommended by the manufacturer. Alcian blue counterstain were used to detect chondrocytes using the monolayer staining method as described previously [44].

Each stain was performed in duplicate for each sample. Results were then visualised using a Zeiss Axioscop microscope and analysed with Axiovision software (Carl Zeiss Inc., New York, USA).

3. Results

3.1. Isolation of stem cells from term placental tissue

Placental stem cells were isolated from term human placentae and grown on untreated plastic cultureware. The mean cell number within a 25 cm² flask was 9×10^5 . These cells were confluent for passaging about every 2 weeks. Stem cell cultures could be passaged up to five times (about 30 population doublings). All experiments in these studies were performed with cells at passage two and each experiment was repeated three or more times.

Fig. 4. Immunohistochemical localization on paraffin sections of cell surface markers in first trimester (12 week) human placenta. X63 negative control (a) and FDO66Q, a control antibody staining the syncytiotrophoblast layer (b). STRO-1 (c), CD146 (d), CD49a/VLA-1 (e) and 3G5 antibody staining of cells around the vessels (f). 3G5 antibody staining in scattered cells around the vessels (arrows). CD34 (g) and vWF (h) show antibody staining of endothelial cells lining the villous vessels. Panels (a)–(f) show staining with DAB and a haematoxylin counterstain. Panels (g) and (h) show AEC staining and a methyl green counterstain. Images are 400 $\times$ magnification and the scale bar represents 50 μ m. v, Villous vessels; and tr, syncytiotrophoblast cells. Staining of cells is shown by an arrow.

3.2. Western immunoblotting

Western analysis was used to show that STRO-1 and 3G5 were expressed in both PMSC protein extracts and in term placental tissue homogenates ($n = 5$). CD49a/VLA-1 was used as a control as it is expressed in placental tissue and FACS analysis shows PMSCs are positive for this cell surface marker [1]. In placental tissue and PMSC extracts, the CD49a antibody revealed the expected 210 kDa and 80 kDa bands [32] and a minor 70 kDa band (Fig. 1A). The 3G5 antibody (Fig. 1B) detected a predominant, immunoreactive but diffuse band at 15 kDa, and minor bands at 10 kDa and 30 kDa, for both term placental tissue homogenate and PMSC protein extracts. The STRO-1 antibody detected a prominent 27 kDa band for both term placental tissue homogenate and PMSC protein extracts (Fig. 1C). Minor bands at 18 kDa and 50 kDa were also observed. Control blots with NIRS and the IA6.12 antibody showed no bands (Fig. 1A and B respectively).

3.3. Immunocytochemistry on cultured PMSC

Ten independent preparations of PMSCs were analysed qualitatively by immunocytochemistry. The panel of cell surface markers and the signal staining intensities are shown in Table 1. Representative staining on cultured cells is shown in Fig. 2. Cultured cells were negative for XG3 (Fig. 2a), vWF (Fig. 2b), NIRS, trophoblast cell surface markers FDO66Q, CD34 and CD117 (data not shown). Most of the cells (>90%) were positive for 3G5 (Fig. 2c), CD146 (Fig. 2d), CD49a/VLA-1 (Fig. 2e), α -SMA (Fig. 2f), CD105 (data not shown), STRO-1 (Fig. 3g) and CD106 (Fig. 3h).

3.4. Colony forming unit assay

Cultured cells were clonogenic as shown by colony forming unit assay (Fig. 2i). Circular clusters of five or more cells were counted as colonies. Seeding at 100 cells per well resulted in $14.3 \pm 3.6\%$

Fig. 5. Immunohistochemical localization of cell surface markers in term human placenta. XG3 negative control (a) and FDO66Q, a control antibody staining the syncytiotrophoblast layer (b). STRO-1(c), CD146 (d), CD49a/VLA-1 (e) and 3G5 (f) antibody staining in the vascular region of the villous vessels. CD34 (g) and vWF (h) control antibodies staining the endothelial cells of the villous vasculature. Antibodies were used on either frozen (a, b, c, d & f) or paraffin (e, g & h) sections depending on antibody specificity. Panel a and f-h show staining with AEC and a methyl green counterstain. Panels (b)–(e) show staining with DAB and a haematoxylin counterstain. Images are 400 $\times$ magnification and the scale bar represents 50 μ m. v, Villous vessels; and tr, syncytiotrophoblast cells. Staining of cells is shown by an arrow.

(mean $\pm$ SEM) of the total cells per well forming colonies, with an average of 49.8 ± 8.2 cells/colony ($n = 6$, 24 colonies counted for each sample).

3.5. Differentiation of PMSCs into adipocytes, osteocytes and chondrocytes

Cells were also incubated with α -MEM medium supplemented with 10% FCS in each plate as a control (Fig. 3a). PMSCs were tested for their ability to differentiate into osteocytes (Fig. 3b), adipocytes (Fig. 3c) and chondrocytes (Fig. 3d) with incubation in either osteogenic, adipogenic or chondrogenic differentiation media, as shown by positive Alizarin Red, Oil red O and Alcian Blue staining respectively ($n = 6$). Control cells showed no morphological changes during culturing and did not stain with any of the cell-type specific stains described above (data not shown).

3.6. Immunohistochemical localisation of PMSCs in the first trimester and term placenta

Mesenchymal stem cell surface markers STRO-1, 3G5, CD146 and CD49a were chosen for further analysis by immunohistochemistry ($n = 10$). All antibodies, except STRO-1 and 3G5, gave strong signals on cultured PMSCs. STRO-1 and 3G5 antibodies required TSA amplification to visualise the signal. All tissues incubated with control NIRS and X63 showed no immunoreactivity in either first trimester or term placental sections (X63 in Figs. 4a and 5a, NIRS data not shown). Control antibody FDO66Q showed specific immunoreactivity only in syncytiotrophoblast cells, in both first trimester (Fig. 4b) and term placenta (Fig. 5b). CD34 and vWF showed positive staining of endothelial cells in first trimester (Fig. 4g and h, respectively) and term placental villous vasculature (Fig. 5g and h, respectively). In first trimester placental tissue, STRO-1 (Fig. 4c), CD146 (Fig. 4d), CD49a (Fig. 4e) all showed immunoreactivity around the vessels. 3G5 (Fig. 4f) staining was specific to scattered cells around the vessels. In term placental tissue, the spatial distribution of antibody staining was not substantially different to first trimester with STRO-1 (Fig. 5c), CD146 (Fig. 5d), CD49a (Fig. 5e) and 3G5 (Fig. 5f) showing

immunoreactivity around the vessels, and again 3G5 staining was specific to individual scattered cells around the vessels. In term placental sections, larger vessels also showed the same staining pattern with the cell surface markers (data not shown). No immunoreactivity was detected in the cytotrophoblast or syncytiotrophoblast cell types, which were revealed by the Q66 antibody (Figs. 4b, 5b and data not shown).

3.7. Dual-labelling immunofluorescence

Immunofluorescence staining was carried out with the endothelial cell surface marker vWF, and STRO-1 ($n = 5$). The endothelial cell surface marker, rabbit anti-human vWF antibody, was used with a donkey anti-rabbit Cy3 conjugated secondary antibody (Fig. 6a, d) combined with mouse STRO-1 anti-human antibody and a goat anti-mouse FITC-conjugated secondary antibody (Fig. 6b, e) and a blue DAPI counterstain to show cell nuclei (Fig. 6c, f). Fluorescence detection revealed discrete cells staining for the STRO-1 antibody around the vessels of various sizes (Fig. 6b and e). Composite images (Fig. 6c, f) showed immunoreactivity with STRO-1 was localised to the vascular regions of the term placental villi and did not overlap significantly with expression of vWF in endothelial cells that comprised the vessel walls (indicated by arrows in Fig. 6c, f). NIRS and X63 showed no specific staining (data not shown).

4. Discussion

The method of Fukuchi et al. [1], which is used routinely to prepare PMSCs, was employed to prepare cultured cells. Exposing cultured cells to specific media formulations that promote differentiation for 2–3 weeks produced cells that were positive for cell-type specific stains. Differentiation into cells with characteristics of adipocytes, osteocytes and chondrocytes was observed. These PMSCs preparations contained clonogenic cells as revealed by colony forming assays, with a variable frequency of colony forming units that was consistent with other studies [33].

Western analysis revealed that CD49a immunoreactive protein was detected in PMSC, as expected since this cell surface marker is

Fig. 6. Dual-label immunofluorescence staining with STRO-1/vWF (a–f) on term frozen placental sections; vWF antibody staining with Cy3 (red) (a), STRO-1 staining with fluorescein detection (green) (b), combined images of (a), (b) are shown in (c) with a DAPI nuclear counterstain stain. Staining from another placenta with vessels of various sizes is shown in panels (d)–(f). vWF antibody staining with Cy3 (d), STRO-1 staining with fluorescein (e), combined images of (d), (e) are shown in (f) with a DAPI nuclear counterstain stain. vWF antibody staining with Cy3 detection (f). NIRS and X63 controls showed low or no background staining (data not shown). Images are 400 $\times$ magnification and the scale bar is 50 μ m. Arrowheads in (c) and (f) show representative staining of STRO-1 in cells within the vascular region.

used for phenotypic analysis of PMSC [1]. Western analyses revealed STRO-1 and 3G5 immunoreactive proteins were detected in PMSC and term placental extracts, but at low levels since it was necessary to amplify the signals.

Immunocytochemistry revealed the fibroblast-like cells produced by this method stained positively with antibodies to the cell surface markers (CD146, CD49a, CD105, CD106 and α -SMA STRO-1, 3G5, and CD49a), which have been used to identify MSCs and PMSCs using FACS analysis. This included antibodies to proteins that have been used to enrich CFU-F populations (CD146, STRO-1, 3G5, and CD49a). As expected, PMSCs were negative for the endothelial cell surface marker vWF and the haematopoietic cell surface marker CD34. Unlike FACS analysis, TSA amplification was necessary to detect 3G5 and STRO-1 staining by immunocytochemistry, and the staining intensity was not uniform in the population. These data are consistent with the notion that PMSCs prepared in this manner are heterogeneous populations. Since cultured cells stain positively for STRO-1 and 3G5 antibodies, and can differentiate along the mesenchymal stem cell lineage, we propose that STRO-1 and 3G5 are cell surface markers for cultured PMSCs. We successfully prepared PMSCs as revealed by the ability of the cells to differentiate into multiple cell types, CFU assays and the immunocytochemical detection of cell staining with a panel of MSC cell surface markers.

Immunohistochemical analysis on first trimester and term placental sections was used to identify the stem cell niche. Immunohistochemical staining with antibodies that have been used to enrich CFU-F populations in MSCs preparations and that are associated with mesenchymal and perivascular cells (STRO-1, 3G5, CD146 and CD49a), produced consistent staining patterns around the blood vessels. The staining distribution between first trimester and term placenta was similar, suggesting that the spatial location of the niche does not change substantially after the first trimester. The vascular staining pattern of STRO-1, 3G5, CD146 is consistent with that seen for these antibodies in human adipose tissues [18] and in the human endometrium for CD146 [45] and these data were used to identify a vascular niche in these tissues. Recently, the frizzled-9 antibody (FZD-9) was shown to be a cell surface marker for PMSCs and can also be used to enrich the CFU-F population [10,34]. The FZD-9 antibody also detects cells in a vascular niche in the term placenta [10]. These data further support a vascular niche within the chorionic villi.

Dual-label fluorescence immunohistochemistry with STRO-1 and vWF further refined the niche to scattered cells around the vessels. There was no significant overlap in STRO-1 staining with vWF staining of the endothelial cells that line the vessels and this is consistent with previous findings by others [15]. These data are consistent with the proposed model of MSCs lying in, or attached to, the basement membrane opposed to endothelial cells [35]. Mesenchymal stem cells have been shown to exhibit a perivascular cell phenotype both *in vitro* and *in vivo* [18,35]. In response to intrinsic and extrinsic factors, the PMSCs would give rise to committed progenitors that incorporate into the surrounding stroma to effect maintenance and repair.

There may be multiple subpopulations of PMSCs in the vascular niche. STRO-1 and 3G5 are cell surface markers for pericytes [15,36–38] and therefore it is likely that one subpopulation of PMSCs detected by these antibodies in the chorionic villi are pericyte-like cells, or they are indeed pericytes. *In vivo* studies have provided evidence that pericytes might act as a source of undifferentiated cells during adipose and osseous tissue repair [39,40]. The possibility that MSCs are derived from pericyte cells has been raised in several studies [15,18,38,41,42]. Mouse gene knockout studies highlight the critical importance of pericytes in the maturation and stability of the placental vasculature [43]. We propose

that the pericyte-like PMSCs contribute to the pool of recruited cells, which respond to growth factors and cytokines derived from the local villous microenvironment, and which subsequently regulate vessel maturation and stabilization within the chorionic villi of the human placenta.

Acknowledgements

We wish to acknowledge the financial support of NHMRC Grant No. 509178, the RWH Foundation, Cecilia Kilkeary Foundation, Eirene Lucas Foundation, Harold & Cora Brennen Benevolent Trust (Equity Trustees), Jack Brockhoff Foundation, J & R McGauran Charitable Trust, Diana Brown Trust (Perpetual Trustees), Helen Macpherson Smith Trust, Thomas R & Rosalinda B Ditchfield Medical Research Endowment Fund and the Wenkart Foundation. Term placental samples were sourced and collected by the research midwives Sue Nisbet and Sue Duggan. There are no conflicts of interest with respect to the authors of this work.

References

- [1] Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. *Stem Cells* 2004;22:649–58.
- [2] Chien CC, Yen BL, Lee FK, Lai TH, Chen YC, Chan SH, et al. In vitro differentiation of human placenta-derived multipotent cells into hepatocyte-like cells. *Stem Cells* 2006;24:1759–68.
- [3] Wulf GG, Viereck V, Hemmerlein B, Haase D, Vehmeier K, Pukrop T, et al. Mesengenic progenitor cells derived from human placenta. *Tissue Eng* 2004;10:1136–47.
- [4] Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S, Takashi TA. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. *Cytotherapy* 2004;6:543–53.
- [5] Zhang X, Mitsuru A, Igura K, Takahashi K, Ichinose S, Yamaguchi S, et al. Mesenchymal progenitor cells derived from chorionic villi of human placenta for cartilage tissue engineering. *Biochem Biophys Res Commun* 2006;340:944–52.
- [6] Li CD, Zhang WY, Li HL, Jiang XX, Zhang Y, Tang P, et al. Isolation and identification of a multilineage potential mesenchymal cell from human placenta. *Placenta* 2005.
- [7] Miao Z, Jin J, Chen L, Zhu J, Huang W, Zhao J, et al. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. *Cell Biol Int* 2006;30:681–7.
- [8] Li D, Wang GY, Dong BH, Zhang YC, Wang YX, Sun BC. Biological characteristics of human placental mesenchymal stem cells and their proliferative response to various cytokines. *Cells Tissues Organs* 2007;186:169–79.
- [9] Chang CM, Kao CL, Chang YL, Yang MJ, Chen YC, Sung BL, et al. Placenta-derived multipotent stem cells induced to differentiate into insulin-positive cells. *Biochem Biophys Res Commun* 2007;357:414–20.
- [10] Battula VL, Bareiss PM, Trembl S, Conrad S, Albert I, Hojak S, et al. Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. *Differentiation* 2007;75:279–91.
- [11] Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, Holzgreve W, et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. *Am J Obstet Gynecol* 2006;194:664–73.
- [12] Fuchs E, Tumber T, Guasch G. Socializing with the neighbors: stem cells and their niche. *Cell* 2004;116:769–78.
- [13] Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. *Nat Rev Mol Cell Biol* 2008;9:11–21.
- [14] Scadden DT. The stem-cell niche as an entity of action. *Nature* 2006;441:1075–9.
- [15] Shi S, Gronthos S. Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. *J Bone Miner Res* 2003;18:696–704.
- [16] Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, et al. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci USA* 2003;100:5807–12.
- [17] Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Ibrahim J, et al. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet* 2004;364:149–55.
- [18] Zannettino AC, Paton S, Arthur A, Khor F, Itescu S, Gimble JM, et al. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype *in vitro* and *in vivo*. *J Cell Physiol* 2008;214:413–21.
- [19] Garcia-Pacheco JM, Oliver C, Kimatrat M, Blanco FJ, Olivares EG. Human decidua stromal cells express CD34 and STRO-1 and are related to bone marrow stromal precursors. *Mol Hum Reprod* 2001;7:1151–7.
- [20] Zannettino AC, Paton S, Kortessidis A, Khor F, Itescu S, Gronthos S. Human multipotential mesenchymal/stromal stem cells are derived from a discrete

- subpopulation of STRO-1bright/CD34⁺/CD45(-)/glycophorin-A-bone marrow cells. *Haematologica* 2007;92:1707–8.
- [21] Bensidhoum M, Chapel A, Francois S, Demarquay C, Mazurier C, Fouillard L, et al. Homing of in vitro expanded Stro-1⁻ or Stro-1⁺ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. *Blood* 2004;103:3313–9.
 - [22] Simmons PJ, Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. *Blood* 1991;78:55–62.
 - [23] Owen M. Marrow stromal stem cells. *J Cell Sci Suppl* 1988;10:63–76.
 - [24] Rider DA, Nalathamby T, Nurcombe V, Cool SM. Selection using the alpha-1 integrin (CD49a) enhances the multipotentiality of the mesenchymal stem cell population from heterogeneous bone marrow stromal cells. *J Mol Histol* 2007;38:449–58.
 - [25] Deschaseaux F, Gindraux F, Saadi R, Obert L, Chalmers D, Herve P. Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45med, low phenotype. *Br J Haematol* 2003;122:506–17.
 - [26] Murthi P, Doherty V, Said J, Donath S, Brennecke SP, Kalionis B. Homeobox gene HLX1 expression is decreased in idiopathic human fetal growth restriction. *Am J Pathol* 2006;168:511–8.
 - [27] Mueller UW, Hawes CS, Jones WR. Identification of extra-villous trophoblast cells in human decidua using an apparently unique murine monoclonal antibody to trophoblast. *Histochem J* 1987;19:288–96.
 - [28] Hawes CS, Petropoulos A, Lopata A, Kalionis B, Jones WR. Reactivity of human trophoblast monoclonal antibodies with marmoset monkey trophoblast cultures. *Hum Reprod* 1998;13:1169–74.
 - [29] Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortessidis A, et al. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. *J Cell Sci* 2003;116:1827–35.
 - [30] Strakova Z, Livak M, Krezalek M, Ihnatovych I. Multipotent properties of myofibroblast cells derived from human placenta. *Cell Tissue Res* 2008.
 - [31] Yoshimura K, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. *J Cell Physiol* 2006;208:64–76.
 - [32] Aboagye-Mathiesen G, Laugesen J, Zdravkovic M, Ebbesen P. Isolation and characterization of human placental trophoblast subpopulations from first-trimester chorionic villi. *Clin Diagn Lab Immunol* 1996;3:14–22.
 - [33] Gronthos S, Mankani M, Brahimi J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. *Proc Natl Acad Sci USA* 2000;97:13625–30.
 - [34] Battula VL, Trembl S, Abele H, Buhning HJ. Prospective isolation and characterization of mesenchymal stem cells from human placenta using a frizzled-9-specific monoclonal antibody. *Differentiation* 2008;76:326–36.
 - [35] da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. *J Cell Sci* 2006;119:2204–13.
 - [36] Anderson DR, Davis EB. Glaucoma, capillaries and pericytes. 2. Identification and characterization of retinal pericytes in culture. *Ophthalmologica* 1996;210:263–8.
 - [37] Nayak RC, Berman AB, George KL, Eisenbarth GS, King GL. A monoclonal antibody (3G5)-defined ganglioside antigen is expressed on the cell surface of microvascular pericytes. *J Exp Med* 1988;167:1003–15.
 - [38] Doherty MJ, Ashton BA, Walsh S, Beresford JN, Grant ME, Canfield AE. Vascular pericytes express osteogenic potential in vitro and in vivo. *J Bone Miner Res* 1998;13:828–38.
 - [39] Richardson RL, Hausman GJ, Campion DR. Response of pericytes to thermal lesion in the inguinal fat pad of 10-day-old rats. *Acta Anat (Basel)* 1982;114:41–57.
 - [40] Diaz-Flores L, Gutierrez R, Lopez-Alonso A, Gonzalez R, Varela H. Pericytes as a supplementary source of osteoblasts in periosteal osteogenesis. *Clin Orthop Relat Res* 1992;280–6.
 - [41] Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem Cells* 2001;19:180–92.
 - [42] Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, Canfield AE. Chondrogenic and adipogenic potential of microvascular pericytes. *Circulation* 2004;110:2226–32.
 - [43] Ohlsson R, Falck P, Hellstrom M, Lindahl P, Bostrom H, Franklin G, et al. PDGFB regulates the development of the labyrinthine layer of the mouse fetal placenta. *Dev Biol* 1999;212:124–36.
 - [44] Thomas D, Sunter A, Gentry A, Agamemnon E. Inhibition of chondrocyte differentiation in vitro by constitutive and inducible overexpression of the c-fos proto-oncogene. *J Cell Sci* 2000;113:439–50.
 - [45] Schwab KE, Gargett CE. Co-expression of two perivascular cell markers isolates mesenchymal stem-like cells from human endometrium. *Hum Reprod* 2007;22:2903–11.